Seres Therapeutics (MCRB) Stock Analysis & Winston Score

Winston Score History

Seres Therapeutics is a biotechnology company that develops medicines made from living microorganisms found in the human gut. Its main product is Vowst (formerly SER-109), an oral capsule that uses purified bacterial spores to treat recurrent *Clostridioides difficile* (C. diff) infections — a dangerous gut infection that keeps coming back in some patients. Seres was the first company to win FDA approval for a microbiome-based oral therapy, which it achieved in 2023.

The company earns revenue primarily through product sales of Vowst in the United States, with Nestlé Health Science as a commercial partner. Despite a high gross margin on the product itself, Seres spends heavily on research and operations, resulting in large operating losses. Its pipeline includes additional microbiome therapies targeting other conditions, but the company faces significant risk around whether Vowst can achieve broad commercial adoption fast enough to support the business before it needs additional funding.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+121.6% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

24.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~1 months

$16M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Seres Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Profit after running costs

Operating Margin

-2890.4%

Losing money on operations — -2890.4%

Return on the money invested

ROCE

-243.3%

Weak — -243.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-3592.9%

Burning cash (-3592.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial